CS McKee’s Supernus Pharmaceuticals SUPN Stock Holding History

CS McKee’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$798K	Sell	33,650 -500	-1%	-$12.1K	0.07%	89
2019 Q3	$938K	Hold	34,150	–	–	0.08%	82
2019 Q2	$1.13M	Sell	34,150 -1,000	-3%	-$34.3K	0.1%	75
2019 Q1	$1.23M	Sell	35,150 -2,400	-6%	-$89.3K	0.11%	77
2018 Q4	$1.25M	Buy	37,550 +200	+0.5%	+$8.6K	0.12%	76
2018 Q3	$1.88M	Hold	37,350	–	–	0.15%	71
2018 Q2	$2.23M	Sell	37,350 -3,900	-9%	-$202K	0.19%	69
2018 Q1	$1.89M	Sell	41,250 -1,500	-4%	-$62.6K	0.15%	71
2017 Q4	$1.7M	Hold	42,750	–	–	0.13%	72
2017 Q3	$1.71M	Buy	42,750 +700	+2%	+$30.3K	0.13%	71
2017 Q2	$1.81M	Buy	42,050 +200	+0.5%	+$7.12K	0.14%	69
2017 Q1	$1.31M	Sell	41,850 -400	-0.9%	-$10.7K	0.1%	78
2016 Q4	$1.07M	Sell	42,250 -3,450	-8%	-$77.1K	0.08%	86
2016 Q3	$1.13M	Sell	45,700 -5,900	-11%	-$134K	0.07%	84
2016 Q2	$1.05M	Buy	+51,600	New	+$915K	0.04%	87

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CS McKee's SUPN Position: Q4 2019 in Review

CS McKee reduced its Supernus Pharmaceuticals (SUPN) stake by 1.5% in Q4 2019, selling an estimated $12.1K and leaving 33,650 shares worth $798K. The position accounts for 0.07% of the portfolio, ranked #89.

CS McKee first reported a position in SUPN in Q2 2016 and has held it in 15 quarters since. The position peaked at $2.23M in Q2 2018. 235 funds tracked by Wall St. Rank hold SUPN as of Q4 2019.

CS McKee held 33,650 shares of Supernus Pharmaceuticals worth $798K as of Q4 2019.
CS McKee sold 500 Supernus Pharmaceuticals shares in Q4 2019, an estimated $12.1K.
Supernus Pharmaceuticals made up 0.07% of CS McKee's portfolio in Q4 2019, its #89 holding.
CS McKee first reported a position in Supernus Pharmaceuticals in Q2 2016 and has held it in 15 quarters since.
CS McKee's Supernus Pharmaceuticals position peaked at $2.23M in Q2 2018.
235 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2019.

Based on CS McKee's 13F filing for Q4 2019, filed 14 Feb 2020.